menu
    • menu
    [{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"National Cancer Institute | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Secretin","moa":"Secretin receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ National Cancer Institute | National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Johns Hopkins University \/ National Cancer Institute | National Institutes of Health"},{"orgOrder":0,"company":"Children's Hospital Medical Center, Cincinnati","sponsor":"CHIRHOCLIN | The National Pancreas Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Secretin","moa":"Secretin receptor","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Children's Hospital Medical Center, Cincinnati","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital Medical Center, Cincinnati \/ CHIRHOCLIN | The National Pancreas Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Children's Hospital Medical Center, Cincinnati \/ CHIRHOCLIN | The National Pancreas Foundation"},{"orgOrder":0,"company":"CHIRHOCLIN","sponsor":"Dartmouth-Hitchcock Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Secretin","moa":"Secretin receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"CHIRHOCLIN","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CHIRHOCLIN \/ Dartmouth-Hitchcock Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"CHIRHOCLIN \/ Dartmouth-Hitchcock Medical Center"},{"orgOrder":0,"company":"CHIRHOCLIN","sponsor":"Dartmouth-Hitchcock Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Secretin","moa":"Secretin receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CHIRHOCLIN","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CHIRHOCLIN \/ Dartmouth-Hitchcock Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"CHIRHOCLIN \/ Dartmouth-Hitchcock Medical Center"}]

    Find Clinical Drug Pipeline Developments & Deals for Secretin

    Menu

    Secretin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CHIRHOCLIN

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            CHIRHOCLIN

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Secretin

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Sponsor : Dartmouth-Hitchcock Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Secretin for Acute Pancreatitis

                            Details : Secretin is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pancreatitis.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            September 27, 2018

                            Lead Product(s) : Secretin

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Sponsor : Dartmouth-Hitchcock Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Children's Hospital Medical Center, Cincinnati

                            Country arrow
                            CTAD25
                            Not Confirmed

                            Children's Hospital Medical Center, Cincinnati

                            Country arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Secretin

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : CHIRHOCLIN | The National Pancreas Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics

                            Details : Secretin is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 17, 2016

                            Lead Product(s) : Secretin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : CHIRHOCLIN | The National Pancreas Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Johns Hopkins University

                            Country arrow
                            CTAD25
                            Not Confirmed

                            Johns Hopkins University

                            Country arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Secretin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : National Cancer Institute | National Institutes of Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Cancer of the Pancreas Screening-5 CAPS5)Study

                            Details : Secretin is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pancreatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 03, 2013

                            Lead Product(s) : Secretin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : National Cancer Institute | National Institutes of Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CHIRHOCLIN

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            CHIRHOCLIN

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Secretin

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I/ Phase II

                            Sponsor : Dartmouth-Hitchcock Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Secretin Infusion for Pain Due to Chronic Pancreatitis

                            Details : Secretin is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Pancreatitis, Chronic.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 23, 2010

                            Lead Product(s) : Secretin

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Dartmouth-Hitchcock Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth